Information Provided By:
Fly News Breaks for September 29, 2016
ADHD
Sep 29, 2016 | 15:46 EDT
Roth Capital analyst Michael Higgins lowered his price target for Alcobra to $7.50 from $12 after the company announced that the FDA would be placing a full clinical hold on its primary asset, MDX, which had been expected to report pivotal trial results in Q1 from a trial of 750 patients with ADHD. However, the analyst reiterates a Buy rating on the shares as he continues to believe MDX will reach the primary endpoint in the MEASURE trial.
News For ADHD From the Last 2 Days
There are no results for your query ADHD
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.